[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gdm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gdm":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,90,117,137,160,182],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100651674","couple-coordinated-lifestyle-intervention-for-women-with-a-history-of-gestational-diabetes-mellitus-100651674",false,"NCT07762625","Couple-Coordinated Lifestyle Intervention for Women With a History of Gestational Diabetes Mellitus","Effectiveness of a Couple-Coordinated Lifestyle Intervention Among Women With a History of Gestational Diabetes Mellitus","Inclusion Criteria:\n\n1. For women:\n\n   * 20 to 40 years of age.\n   * Diagnosed with gestational diabetes mellitus during the most recent pregnancy.\n   * Have basic literacy and sufficient cognitive and physical ability to participate in the study.\n   * Living with their spouse.\n   * Able to use a smartphone.\n   * Willing to participate in the study.\n2. For spouses:\n\n   * Living with an eligible woman with a history of gestational diabetes mellitus.\n   * Have basic literacy and sufficient cognitive and physical ability to participate in the study.\n   * Able to use a smartphone.\n   * Willing to participate in the study.\n\nExclusion Criteria:\n\n1. For women:\n\n   * Diabetes diagnosed before pregnancy or after delivery.\n   * Pregnant at the time of screening.\n   * Currently using medications that affect glucose metabolism or medications for weight loss.\n   * Cognitive impairment or a serious psychiatric disorder.\n   * A contraindication to postpartum exercise.\n   * Current participation in another lifestyle intervention program.\n2. For spouses:\n\n   * A diagnosed major chronic disease, such as coronary heart disease or diabetes, or another serious physical illness.\n   * Cognitive impairment or a serious psychiatric disorder.\n   * Current participation in another lifestyle intervention program.\n\nWomen with a history of gestational diabetes mellitus and their spouses will be recruited during postpartum follow-up visits at the participating hospitals. Both members of the couple must meet their respective eligibility criteria.",true,"ALL","20 Years","40 Years",{"count":21,"type":22},362,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this clinical trial is to evaluate the effects of a couple-based collaborative lifestyle intervention among women with a history of gestational diabetes. The main questions it aims to answer are:\n\nDoes the intervention improve body mass index and 2-hour plasma glucose after an oral glucose tolerance test? Does the intervention improve health behaviors, psychological well-being, self-efficacy, couple functioning, and life satisfaction?\n\nResearchers will compare a couple-based collaborative lifestyle intervention with a woman-only lifestyle intervention to determine whether adding spousal collaboration and support leads to greater improvements.\n\nParticipants will:\n\nReceive healthy lifestyle education posts for 3 months. In the couple-based group, also receive instant messages on behavioral promotion and couple collaboration and support videos.",[28,29,30,31,32],"Diabetes Prevention","GDM","Lifestyle Intervention","Couples","Postpartum","NOT_YET_RECRUITING","2026-08-08",{"date":36,"type":37},"2026-08-13","ACTUAL",{"date":39,"type":22},"2026-08-15",{"date":41,"type":22},"2028-08-30",{"name":43,"class":44},"The Third Xiangya Hospital of Central South University","OTHER",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100648140","healthy-habits-during-and-after-gestational-diabetes-100648140","NCT07717515","Healthy Habits During and After Gestational Diabetes","Healthy Habits During and After Gestational Diabetes: A Cluster Randomised Family Intervention Controlled Trial in Northern Vietnam (VALID III)","VALID III","Inclusion Criteria:\n\n* Confirmed GDM diagnosis in the current pregnancy according to WHO criteria and enrolled no longer than seven days after diagnosis.\n* Gestational age at enrolment ≤ 28+0 weeks of pregnancy.\n* Maternal age ≥18 years at consent.\n* Pregnancy with singleton gestation\n* Residence within the study catchment area.\n* Language proficiency sufficient to complete consent and study procedures in Vietnamese.\n* Capacity to provide informed consent and willingness to participate in all trial procedures, including randomisation\n\nExclusion Criteria:\n\n* Pregestational diabetes (type 1 or type 2) diagnosed prior to this pregnancy.\n* Severe chronic medical conditions and chronic severe mental health conditions likely to interfere with participation, safety, or outcome assessment (e.g., advanced cardiac, renal, hepatic disease; active malignancy; severe uncontrolled endocrine disease other than GDM, schizophrenia, active psychosis).\n* Inability to provide informed consent .\n* Pregnant women with multiple gestations.\n* Pregnant women where it is biologically impossible for the woman to breastfeed, e.g., the woman has undergone bilateral mastectomy.\n* Any other condition that, in the judgment of the investigators, makes participation inappropriate or infeasible, e.g., surrogate mother.","FEMALE","18 Years",{"count":57,"type":22},2546,[25],"Gestational diabetes mellitus (GDM) is associated with an increased risk of childhood obesity and other adverse health outcomes. Early-life nutrition, particularly exclusive breastfeeding, plays an important role in reducing this risk. In Vietnam, infant feeding and childcare practices are strongly influenced by family members, including husbands, grandparents, and parents-in-law.\n\nThe Healthy Habits During and After Gestational Diabetes (VALID III) trial aims to evaluate the effect of a co-created family-based health intervention on improving infant feeding practices and childhood body composition among children born to women with GDM. The intervention includes counseling, peer support, digital health components, educational materials, and follow-up support for nutrition, infant feeding practices, physical activity, and GDM management from pregnancy through 24 months after birth. Participants in the control group will receive standard care together with access to a GDM management website.\n\nThe primary objective is to evaluate the effect of the intervention on the duration of exclusive breastfeeding during the first 180 days after birth. Secondary objectives include evaluating exclusive breastfeeding at 6 months, child fat mass index at 24 months, and broader maternal and child health and wellbeing outcomes.",[29],[62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79],"Gestational diabetes mellitus","exclusive breastfeeding","infant feeding","pregnancy hyperglycaemia","early-life nutrition","child adiposity","fat mass index","childhood obesity","lifestyle intervention","behavioural intervention","family-based intervention","caregiver involvement","maternal nutrition","physical activity","postpartum health","complementary feeding","Vietnam","low- and middle-income countries","2026-07-20",{"date":82,"type":37},"2026-07-22",{"date":84,"type":22},"2026-11-15",{"date":86,"type":22},"2030-08-30",{"name":88,"class":44},"Thai Binh University of Medicine and Pharmacy",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":16,"sex":54,"minAge":55,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":4},"100643973","advancing-stillbirth-prevention-through-innovative-risk-evaluation-aspire-clinical-study-100643973","NCT07669935","Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study","A Multi-Site, Prospective, Two-Part Longitudinal, Observational Cohort Study Of Pregnant Women To Evaluate Biomarkers For Prediction Of Pregnancy Complications","ASPIRE","Inclusion Criteria:\n\n* Age ≥18 years\n* Nulliparous (no previous births ≥20wk GA)\n* Single viable fetus at the dating ultrasound scan with an ultrasound estimated gestational age of 10 0\u002F7-17 6\u002F7 weeks of gestation\n* Ability to consent and comply with study procedures and follow-up\n\nExclusion Criteria:\n\n* Multiple gestation\n* Inability to provide blood\n* Known fetal chromosomal abnormalities or structural Anomaly (a structural or functional defect with the following three characteristics: 1) of prenatal origin; 2) present at the time of live birth or fetal demise, or in utero; 3) affecting (or has the propensity to affect) the health, survival, or physical or cognitive functioning of the individual\n* Known or anticipated inability to complete study follow-up through delivery at the study site (e.g., planned relocation, transfer of obstetric care to a non-participating institution, or other circumstances making delivery outcome data unavailable)\n* Current or recent (within two months) participation in an interventional clinical study.","99 Years",{"count":100,"type":22},5500,"OBSERVATIONAL","ASPIRE will be a multi-site, prospective, two-part longitudinal, noninterventional observational cohort study of nulliparous singleton pregnant women to evaluate biomarkers from blood and ocular imaging for prediction of pregnancy complications \\[i.e., preeclampsia (PE), fetal growth restriction (FGR), and gestational diabetes (GDM)\\] and risk of adverse outcomes.",[29,104,105,106,107],"Preterm Preeclampsia","Preeclampsia","Fetal Growth Restriction (FGR)","Pregnancy Complications","2026-06-25",{"date":110,"type":37},"2026-06-29",{"date":112,"type":22},"2026-07-30",{"date":114,"type":22},"2028-12-01",{"name":116,"class":44},"Medicines360",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":54,"minAge":55,"maxAge":19,"enrollmentInfo":124,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":122,"conditions":126,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":89},"100613194","gestational-lifestyle--outcomes-wellness-100613194","NCT07263412","Gestational Lifestyle & Outcomes Wellness","A Multicenter Prospective Cohort Study to Identify Risk Factors and Develop a Diagnostic Prediction Model for Gestational Diabetes Mellitus, and to Evaluate the Effectiveness of Multidisciplinary Precision Health Interventions (GLOW Plan)","Inclusion Criteria: All must be met\n\n1. Aged 18-40 years;\n2. Pre-pregnancy BMI: 18.5 kg\u002Fm² \\\u003C BMI \\\u003C 28 kg\u002Fm²;\n3. Able to read, understand and sign the informed consent form;\n4. Receive prenatal care and deliver in the study hospital.\n\nExclusion Criteria: Any one met leads to exclusion\n\n1. Twin or multiple pregnancies;\n2. Pre-gestational diabetes mellitus (PGDM), including new-onset diabetes during pregnancy;\n3. Poorly controlled pre-pregnancy chronic hypertension (BP ≥140\u002F90 mmHg);\n4. Complicated with severe liver\u002Fkidney diseases;\n5. Current\u002Frecent use of drugs affecting glucose metabolism;\n6. Mental illness or severe psychological disorders;\n7. Complicated with severe infection;\n8. Poor compliance or refusal to use CGM\u002FSMBG.",{"count":125,"type":22},1000,[29],"RECRUITING","2025-11-24",{"date":130,"type":37},"2025-12-04",{"date":132,"type":37},"2025-02-25",{"date":134,"type":22},"2028-11",{"name":136,"class":44},"The First Affiliated Hospital with Nanjing Medical University",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":16,"sex":54,"minAge":55,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":89},"100603796","effect-of-early-lifestyle-intervention-on-perinatal-outcomes-in-high-risk-women-for-gestational-hyperglycemia-100603796","NCT07141173","Effect of Early Lifestyle Intervention on Perinatal Outcomes in High-risk Women for Gestational Hyperglycemia","Inclusion Criteria:\n\n* 18-55 years old\n* 6-14 weeks of pregnancy\n* at least one risk factor for GDM\n* signed a written informed consent\n\nExclusion Criteria:\n\n* Individuals diagnosed with diabetes or prediabetes prior to pregnancy\n* currently taking medications affecting blood glucose levels such as metformin\n* women at risk of miscarriage\n* individuals with chronic conditions (such as uncontrolled hypertension, severe heart disease)\n* those with movement disorders or contraindicated conditions for physical activity\n* patients undergoing gastrointestinal surgeries that alter glucose absorption\n* those unable to maintain regular prenatal care (such as non-compliance with medical instructions or mental health issues).","45 Years",{"count":145,"type":22},604,[25],"This study aims to explore whether early intervention for high-risk groups of gestational hyperglycemia can improve insulin resistance and effectively prevent the occurrence of GDM, and evaluate which pathophysiological subtypes of GDM have the best effect on improving maternal and fetal adverse prognosis, so as to provide evidence for stratified management and individualized clinical intervention of high glucose groups in pregnancy",[29],[29,150],"RCT","2025-08-25",{"date":153,"type":37},"2025-08-26",{"date":155,"type":22},"2025-08-20",{"date":157,"type":22},"2027-08-20",{"name":159,"class":44},"Tianjin Central Hospital of Gynecology Obstetrics",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":168,"targetDuration":4,"studyType":101,"phases":4,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":89},"100377276","digestnewborn-study-100377276","NCT04192422","DiGESTnewborn Study","Glucose Control and Metabolic Adaptation in Offspring of Women With Gestational Diabetes Recruited to the DiGest Study","DiGESTnewborn","Inclusion Criteria:\n\n* mothers and their babies who have been enrolled in DiGest Trial and who have provided informed consent\n\nExclusion Criteria:\n\n* none",{"count":169,"type":22},60,"We wish to study the effect of a mothers sugar (glucose) control during pregnancy on her baby's sugar control after birth.",[29,172],"Hypoglycemia","2025-04-15",{"date":175,"type":37},"2025-04-17",{"date":177,"type":37},"2020-09-01",{"date":179,"type":22},"2026-12-31",{"name":181,"class":44},"Cambridge University Hospitals NHS Foundation Trust",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":16,"sex":17,"minAge":55,"maxAge":189,"enrollmentInfo":190,"targetDuration":4,"studyType":23,"phases":192,"briefSummary":193,"conditions":194,"keywords":4,"overallStatus":127,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":89},"100585394","efficacy-of-lactobacillus-rhamnosus-lra05-in-gestational-diabetes-100585394","NCT06901791","Efficacy of Lactobacillus Rhamnosus LRa05 in Gestational Diabetes","Assessing the Efficacy of Lactobacillus Rhamnosus LRa05 in Improving Blood Glucose and Gut Microbiota in Patients With Gestational Diabetes","Inclusion Criteria:\n\n1. Women diagnosed with gestational diabetes mellitus (GDM) at 24 weeks of gestation.\n\n   Diagnostic criteria for GDM: Abnormal oral glucose tolerance test (OGTT) with an 82.5g glucose load during the 24th week of pregnancy (defined as meeting one or more of the following plasma glucose thresholds: fasting ≥ 5.1 mmol\u002FL, 1-hour ≥ 10 mmol\u002FL, or 2-hour ≥ 8.5 mmol\u002FL).\n2. Pregnant women aged 18 to 50 years.\n3. Singleton pregnancy with a fetus confirmed to be structurally and chromosomally normal via ultrasound or other prenatal diagnostic methods.\n4. No history of chronic diseases, including immune deficiency, hypertension, diabetes, kidney disease, or liver disease.\n5. No consumption of probiotic-containing foods (e.g., yogurt, fermented foods, soybean paste) within the two weeks prior to the study.\n6. Willing and able to provide written informed consent.\n7. Capable of complying with the study protocol and follow-up requirements.\n\nExclusion Criteria:\n\n1. Those who have taken items with similar functions to the test product in the short term, which may affect the judgment of the results.\n2. Those with other endocrine diseases or currently using medications that affect blood glucose control.\n3. Those with severe cardiovascular, kidney, or liver diseases.\n4. Those with immunodeficiency diseases or currently using immunosuppressive agents.\n5. Those with severe gastrointestinal diseases that may affect the absorption or metabolism of probiotics.\n6. Those currently using other medications that may affect blood glucose control or lipid levels.\n7. Those with a history of allergy to probiotics or any components of the study products.\n8. Those with unhealthy lifestyle habits, such as smoking, alcohol consumption, or drug abuse.\n9. Those who do not consume the test samples as required or do not follow up on time, resulting in uncertain efficacy.\n10. Study participants deemed unsuitable by other researchers.","50 Years",{"count":191,"type":22},80,[25],"This study aims to comprehensively evaluate the multifaceted impacts of Lactobacillus rhamnosus LRa05 on patients with gestational diabetes. Initially, the study will investigate the effects of LRa05 on improving patients' blood glucose levels and gut microbiota. Additionally, the study will assess the impact of this strain on patients' blood lipid levels, inflammatory markers, and body mass index (BMI). Furthermore, the study will also focus on its effects on thyroid function, vaginal microbiota, and bile acid metabolism in patients with gestational diabetes.",[29],"2025-03-28",{"date":197,"type":37},"2025-03-30",{"date":199,"type":22},"2025-04-10",{"date":201,"type":22},"2026-03-10",{"name":203,"class":204},"Wecare Probiotics Co., Ltd.","INDUSTRY"]